The Authors Reply: Harris points out the potential risk of giving a beta-lactam antibiotic to a patient with a documented penicillin allergy. Although our patient did report a history of an allergy to penicillin, we explored this history in more detail before prescribing antibiotics. She described a nonspecific rash after receiving penicil-
1.
lin in the past, but a record review indicated that she had subsequently tolerated several courses of beta-lactams, including piperacillin-tazobactam, without incident. In many patients who report a history of penicillin hypersensitivity, penicillinspecific IgE antibodies are not detected on skin testing. 1 In this case, although we did not have information from skin testing, we considered the patient's tolerance of piperacillin-tazobactam on previous occasions to be reassuring. No adverse reaction to the beta-lactam was noted on this occasion, despite careful observation for signs and symptoms. 

Reversal of Type 1 Diabetes in Mice
To the Editor: Dr. Melton (July 6 issue) 1 misrepresents my study on the reversal of type 1 diabetes in mice and its implications for new treatment strategies in humans. 2 As in a previous study, 3 my colleagues and I discovered that an immune therapy triggered a permanent reversal of end-stage type 1 diabetes in mice. The treatment involved two components: injecting the mice with an immune adjuvant (to induce the production of tumor necrosis factor, which destroys autoreactive T cells) and injecting splenocytes from a donor mouse.
Dr. Melton writes that we ascribed the reversal of type 1 diabetes in a mouse model solely to the transplantation of spleen cells and that we claimed to have identified a stem cell among the donor splenocytes that contributed to regrowth of the islets in the recipient. It is true that we observed adult stem cells and that these cells can contribute, in part, to the regrowth of the islets. However, Dr. Melton does not acknowledge that we also observed regeneration of pancreatic islets and complete reversal of type 1 diabetes without the introduction of any live donor splenocytes. 2 Infusion of live splenic cells hastened the development of permanent normoglycemia in the mice but did not enhance the rate of cure. We did not claim that the regenerative process required a stem cell, and we did not rule out other mechanisms, such as regrowth or rescue of host islets. Our research simply found regeneration of the pancreas once the autoimmune process was removed.
Instead of cheering the fact that our laboratory's immunomodulatory approach was replicated successfully by three recent studies, 4-6 Dr. Melton places emphasis on the failure of these cited studies to identify a splenocyte contribution to the observed regeneration of the pancreas. It is possible that methodologic differences between our protocol and theirs precluded finding a contribution of splenic stem cells to pancreatic regeneration in these studies. But since then, the optional splenic contribution has been replicated. 7 From a clinical perspective, the existence of an adult stem cell in the spleen seems to be beside the point. Many studies have since shown that the regenerative process in the pancreas is likely to be intact and that targeted immune intervention may unleash the spontaneous regeneration of the pancreas. It seems reasonable to test the hypothesis that for end-stage diabetes, an immune intervention that destroys autoreactive T cells in the mouse can also work in the clinic. 
